The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Abstract
Background No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the efficacy and safety of inebilizumab, an anti-CD19, B cell-depleting antibody, in reducing the risk of attacks and disability in NMOSD. Methods We did a multicentre, double-blind, randomised placebo-controlled phase 2/3 study at 99 outpatient specialty clinics or hospitals in 25 countries. Eligible participants were adults (≥18 years old) with a diagnosis of NMOSD, an Expanded Disability Status Scale score of 8·0 or less, and a history of at least one attack requiring rescue therapy in the year before screening or at least two attacks requiring rescue therapy in the 2 years before screening. Participants were randomly allocated (3:1) to 300 mg intravenous inebilizumab or placebo with a central interactive voice response system or interactive web response system and permuted block randomisation. Inebilizumab or placebo was administered on days 1 and 15. Participants, investigators, and all clinical staff were masked to the treatments, and inebilizumab and placebo were indistinguishable in appearance. The primary endpoint was time to onset of an NMOSD attack, as determined by the adjudication committee. Efficacy endpoints were assessed in all randomly allocated patients who received at least one dose of study intervention, and safety endpoints were assessed in the as-treated population. The study is registered with ClinicalTrials.gov, number NCT02200770. Findings Between Jan 6, 2015, and Sept 24, 2018, 230 participants were randomly assigned to treatment and dosed, with 174 participants receiving inebilizumab and 56 receiving placebo. The randomised controlled period was stopped before complete enrolment, as recommended by the independent data-monitoring committee, because of a clear demonstration of efficacy. 21 (12%) of 174 participants receiving inebilizumab had an attack versus 22 (39%) of 56 participants receiving placebo (hazard ratio 0·272 [95% CI 0·150-0·496]; p<0·0001). Adverse events occurred in 125 (72%) of 174 participants receiving inebilizumab and 41 (73%) of 56 participants receiving placebo. Serious adverse events occurred in eight (5%) of 174 participants receiving inebilizumab and five (9%) of 56 participants receiving placebo. Interpretation Compared with placebo, inebilizumab reduced the risk of an NMOSD attack. Inebilizumab has potential application as an evidence-based treatment for patients with NMOSD. Funding MedImmune and Viela Bio.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In any case, the long-term persistence of (re-)activatable autoantigen-specific ThEx cells in patients in remission may well explain the less-than-perfect treatment efficacy of steroid-sparing agents, 64-67 depletion of CD19/CD20 memory B cells, 68,69 as well as exacerbation of disease by b -IFN. 27,70”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [68]
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
Self-citationOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationOcrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationEculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J. A., Nakashima, I., Terzi, M., Totolyan, N. A., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 887
Self-citationAn open label study of the effects of rituximab in neuromyelitis optica
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. L., & Genain, C. P. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Self-citationNeuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Self-citationIntrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis optica
Bennett, J. L., Lam, C., Kalluri, S. R., Saikali, P., Bautista, K., Dupree, C., Glogowska, M. J., Case, D., Antel, J. P., Owens, G. P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21802 · Cited by 593
Self-citationNeuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
Weinshenker, B. G., Wingerchuk, D. M., Vukusic, S., Linbo, L., Pittock, S. J., Lucchinetti, C. F., & Lennon, V. A. (2006) · Annals of Neurology · doi:10.1002/ana.20770 · Cited by 585
Self-citation
Cited by
Sorted by citations
Items 401–500 of 742
Okuda, D. T., Moog, T. M., McCreary, M., Cook, K., Burgess, K. W., & Smith, A. D. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105041 · Cited by 6
Wang, Y., Zhao, M., Yao, M., Yang, Z., Li, B., Yin, L., & Geng, X. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105062 · Cited by 6
Hua, L. H., Obeidat, A. Z., & Longbrake, E. E. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102296 · Cited by 6
“Its growth has been fueled by the increasing specificity with which autoimmune syndromes can be identified (LopezChiriboga and Clardy, 2017; Linnoila and Pittock, 2016) as well as by the expansion of immunomodulatory treatment options for multiple sclerosis (MS) and other central nervous system (CNS) neuroimmune disor…”
BackgroundHerrero-Morant, A., Álvarez-Reguera, C., Martín-Varillas, J. L., Calvo-Río, V., Casado, A., Prieto-Pena, D., Atienza‐Mateo, B., Maiz, O., Blanco, A., Vicente, E. F., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082608 · Cited by 7
Wang, L., Du, L., Li, Q., Li, F., Wang, B., Zhao, Y., Meng, Q., Li, W., Pan, J., Xia, J., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.947974 · Cited by 6
Sivadasan, A., & Bril, V. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.05.002 · Cited by 6
Ponleitner, M., & Rommer, P. S. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00987-2 · Cited by 7
“Accordingly, inebilizumab exhibited good efficacy and safety in the phase II/III N-MOmentum trial ( n = 230) versus placebo [98]; due to the recency of approval, however, long-term data are still missing.”
BackgroundThon, J. M., Sharkus, R., Thakkar, R., Hunter, K. M., Siegler, J. E., & Thon, O. R. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105076 · Cited by 6
Levy, M. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001382 · Cited by 6
Ocrelizumab zur Behandlung der Multiplen Sklerose
Graf, J., Albrecht, P., Goebels, N., Aktaş, O., & Hartung, H. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00937-6 · Cited by 7
Self-citationSimaniv, T. O., Kochergin, I. A., Zakharova, M. N., Korobko, D. S., Zaslavsky, L. G., Зеленова, О. В., & Абрамов, С. И. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202112107196 · Cited by 6
Neuropsychiatric Systemic Lupus Erythematosus: A Remaining Challenge
Mrak, D., Bonelli, M. M., & Radner, H. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220512102824 · Cited by 6
Neuromyelitis Optica Spectrum Disorders
Li, X., & McKeon, A. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00024-5 · Cited by 6
A study on patients with neuromyelitis optica spectrum disorder from Eastern India
Mukherjee, S., Guha, G., Roy, M., Ghosh, S., & Saha, S. P. (2019) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2019.12.003 · Cited by 6
Cree, B., Greenberg, B. M., Cameron, C., & Weinshenker, B. G. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00376-2 · Cited by 6
“The N-MOmentum trial also consistently obtained magnetic resonance imaging data to supplement the clinical attack criteria.”
BackgroundInfluentialSelf-citationLi, S., Gao, Y., He, Y., & Zhang, Z. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1371515 · Cited by 5
Kačerová, T., Sealey, M. A., Saldana, L., Xiong, W., Woodhall, M. R., Waters, P. J., Sénard, T., Cheeseman, J., Urbanowicz, P. A., Elgood-Hunt, G., et al. (2025) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200502 · Cited by 5
Do modern therapies change natural history of Neuromyelitis optica?
Cabre, P. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.07.002 · Cited by 5
Pathomrattanapiban, C., Tisavipat, N., Jitprapaikulsan, J., Prayoonwiwat, N., Rattanathamsakul, N., & Siritho, S. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103882 · Cited by 5
James, J., Gafoor, V., Jose, J., Smita, B., & Balaram, N. (2023) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_59_2022 · Cited by 5
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean
Chaumont, H., Bérard, N., Karam, J., Lobjois, Q., Tressières, B., Signaté, A., Lannuzel, A., & Cabre, P. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200175 · Cited by 5
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder
Balaban, D. T., Levy, M., Borrow, R., & Anderson, M. R. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2423002 · Cited by 5
Takahashi, Y., Kezuka, T., Shikishima, K., Yamagami, A., Chuman, H., Nakamura, M., Ueki, S., Kimura, A., Hashimoto, M., Tatsui, S., et al. (2024) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-024-01129-4 · Cited by 5
Alisch, M., Foersterling, F., Zocholl, D., Muinjonov, B., Schindler, P., Duchnow, A., Otto, C., Ruprecht, K., Schmitz‐Hübsch, T., Jarius, S., et al. (2025) · Glia · doi:10.1002/glia.24675 · Cited by 5
“The hypothesis that cellular infiltrates contribute critically to the pathophysiology also stems from the observation that targeting the cellular elements with immunosuppressive drugs is efficient in treating NMOSD (Cree et al. 2019; Tahara et al. 2020).”
Self-citationChen, X., Wang, R., Li, R., Hu, S., Shi, Z., & Zhou, H. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12937-0 · Cited by 5
Zhou, J., Yang, X., Wang, X., Li, B., Xu, Y., Zhang, H., Zhu, Y., Wang, X., & Feng, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1559118 · Cited by 5
Steinegger, L., Kana, V., Pot, C., Gobbi, C., Weller, M., Roth, P., Théaudin, M., Zecca, C., & Herwerth, M. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106602 · Cited by 5
Mori, S., Kurimoto, T., Murai, Y., Ueda, K., Sakamoto, M., Chihara, N., Yamada‐Nakanishi, Y., & Nakamura, M. (2020) · Journal of Ophthalmology · doi:10.1155/2020/8871146 · Cited by 5
“Inebilizumab binds to CD19 antigen present on the surface of B cells and exclusively depletes B cell lines [33].”
BackgroundImmune reconstitution therapy in NMOSD
Brod, S. A. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102971 · Cited by 5
Elevated IL ‐23 in skin promotes IL ‐23 derived Th17 responses in leprosy patients
Shi, C., Ma, S., Bai, J., Liu, Y., Ma, Y., Lu, X., Zhu, J., & Yang, D. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13689 · Cited by 5
“tuberculoid (TT) and lepromatous (LL), and in between these two clinical forms lies borderline tuberculoid (BT), borderline–borderline (BB), and borderline lepromatous.(6,7) Interleukin-23 (IL-23) is a pro-inflammatory cytokine composed of two subunits, p19 and p40.”
BackgroundDresser, L., Chaar, W. A., Reder, A. T., Abuaf, A. F., Cipriani, V., & Javed, A. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104718 · Cited by 5
Rectifying global inequities in neuromyelitis optica diagnosis and treatment
Mateen, F. J. (2023) · Multiple Sclerosis Journal · doi:10.1177/13524585231179108 · Cited by 5
Lou, C.-Y., Xing, J.-Y., Ma, T., Tao, L., Wang, X., & Wang, R. (2024) · International Journal of Ophthalmology · doi:10.18240/ijo.2024.06.12 · Cited by 5
“This mechanism helps control disease recurrence [4] .”
BackgroundContentti, E. C., López, P. A., Pettinicchi, J. P., Míguez, J., Patrucco, L., Cristiano, E., Liwacki, S., Tkachuk, V. A., Balbuena, M. E., Vrech, C., et al. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123099 · Cited by 5
Plegia to walking: AHSCBMT in severe NMOSD relapse
Carlisle, N., Hari, P., & Brod, S. A. (2020) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000073 · Cited by 5
Central Sleep Apnea Syndrome Can Complicate Neuromyelitis Optica Spectrum Disorder: A Case Report
Morelli, C., Aeby, A., Scaillet, S., Boitsios, G., Vens, D., Prigogine, C., Biarent, D., & Vicinanza, A. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.547474 · Cited by 5
Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19
Yeaman, M. R. (2021) · Glomerular Diseases · doi:10.1159/000519182 · Cited by 5
“11 the neurological autoimmune disease, neuromyelitis optica (NMO; [73]).”
BackgroundMultiple types of relapses in MOG antibody disease
Levy, M., Molazadeh, N., Bilodeau, P., Vishnevetsky, A., Lotan, I., Salky, R., Anderson, M., Romanow, G., Lechner‐Scott, J., Yeh, E. A., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104613 · Cited by 5
Isobe, N., Oda, T., Yamaguchi, T., Kamei, Y., Tsumuraya, T., Yuri, A., Nakasone, A., Asao, K., & Matsuda, S. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00794-y · Cited by 4
“Long-term treatments include oral glucocorticoids, classical immunosuppressants such as azathioprine and mycophenolate mofetil [6, 9], collectively referred to as conventional therapies, and—since 2019—biologics [10–16], all of which potentially increase the risk of infection [6, 8, 17].”
Wright, M. A., Demmitt-Rice, C. E., van Haren, K. P., Lund, T. C., Eichler, F., & Bonkowsky, J. L. (2025) · Journal of Child Neurology · doi:10.1177/08830738251353034 · Cited by 5
Lewis, G., Chan, N. L. S., Frank, B. T., Troitskaya, L. A., Law, B., Edman, U., Fomin, M. E., Chapin, S. J., Punnonen, J., & Capon, D. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-16461-z · Cited by 4
“A cohort of four animals received two doses of HB2198 at 25 mg/kg HB2198, 14 days apart, matching the initial clinical dosing schedule used for both anti-CD19 and anti-CD20 antibodies in the treatment of autoimmune diseases 10,21 .”
Yang, X., Jia, Z., Lian, X., Zhang, R., Li, B., Tian, D., Gao, X., Guo, S., Wang, B., Liu, H., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13408-2 · Cited by 4
Lotan, I., Anderson, M., & Levy, M. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00015-8 · Cited by 4
Soyfoo, M. S., & Sarrand, J. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48010077 · Cited by 4
“Inebilizumab, a humanized monoclonal antibody targeting CD19, induces broad depletion across the B-cell lineage and has been shown to achieve more profound suppression of circulating plasmablast compartments than rituximab, which spares CD19 + plasmablasts and plasma cell precursors [30,117,118].”
Mahler, J. V., Vallejos, G. B., Mikami, T., Bilodeau, P., Anderson, M., Drosu, N. C., Bobrowski‐Khoury, N., Silva, G. D., Solti, M., Apóstolos‐Pereira, S. L., et al. (2026) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200514 · Cited by 6
“8 Thus, it should not be interpreted as evidence to postpone DMTs.”
Bradl, M., Yu, Q., & Takai, Y. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101945 · Cited by 7
Simaniv, T. O., Belkina, A. A., & Zakharova, M. N. (2023) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2023.2.9 · Cited by 4
Akatani, R., Chihara, N., Koto, S., Mori, S., Kurimoto, T., Nakamura, M., Tachibana, H., Otsuka, Y., Ueda, T., Omori, T., et al. (2024) · Immunological Medicine · doi:10.1080/25785826.2024.2304364 · Cited by 4
“B-cell depletion, interleukin (IL)-6 receptor blocking, and complement-targeted therapies have all been successfully developed to treat NMOSD [6–8].”
BackgroundRees, J., Rempe, T., Tuna, İ. S., Montalvo, M., Sabat, S. B., Massini, T. C., & Yetto, J. M. (2024) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2023.12.001 · Cited by 5
Advances in Diagnosis and Management of Atypical Demyelinating Diseases
Hutto, S. K., & Cavanagh, J. J. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.09.011 · Cited by 4
Pathogenic Roles of Age‐Associated B Cells in Neuromyelitis Optica Spectrum Disorder
Amano, E., Sato, W., & Yamamura, T. (2025) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.70012 · Cited by 4
Rezaei, S. J., Vogel, A. C., Gazdag, B., Alakel, N., Kumar, A. R., & Mateen, F. J. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577320 · Cited by 4
Recent advances in the treatment of neuromyelitis optica spectrum disorders
Romeo, A. R. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000791 · Cited by 4
Du, Y., Li, K., Liu, W., Song, R., Luo, M., He, J., Xu, X., & Qu, X. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210329101335 · Cited by 4
Nuclear Imaging of Endogenous Markers of Lymphocyte Response
Alam, I. S., Shaffer, T. M., & Gambhir, S. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_2 · Cited by 4
Massacesi, L., Mariottini, A., & Nicoletti, F. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154288 · Cited by 4
“An anti-CD19 mAb (inebilizumab) is adopted for the treatment of neuromyelitis optica spectrum disorder (NMOSD) [89].”
BackgroundInfluentialUpdate on glial antibody-mediated optic neuritis
Song, H., Zhou, H., & Wei, S. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00932-1 · Cited by 4
“1 3 results of 4 randomized, double-blind, placebo-controlled clinical trials, the United States Food and Drug Administration (FDA) approved eculizumab [55], ineblizumab [56], and satralizumab [57, 58] for the treatment of AQP4-NMOSD in adults.”
BackgroundTargeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders
Liyanage, G., & Brilot, F. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102643 · Cited by 4
Las audiencias y la administración de justicia en las Indias
Martiré, E. (2005) · Universidad Autónoma de Madrid eBooks · Cited by 4
Avasarala, J., Zachariah, P., & Turner, B. (2021) · CNS Spectrums · doi:10.1017/s1092852921000183 · Cited by 4
Wang, X., Guo, R., Yao, Z., Liu, L., Jia, Z., Song, X., & Li, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1556259 · Cited by 3
Boyko, A. N., Zakharova, M. N., Simaniv, T. O., Alifirova, V. M., Arefieva, E. G., Анатольевна, Б. М., Goncharova, Z. A., Greshnova, I. V., Dorogov, N. V., Dudin, V. A., et al. (2025) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2025-4-16-25 · Cited by 3
Huang, W., Lin, R., Zeng, X., Wang, H., & Yan, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1665688 · Cited by 4
Post marketing real-world experience of ravulizumab in NMOSD
Jacob, A., Mahmoud, A., Saab, R. R., Deif, A. A., Lee, G., Elhabet, S., Eldweik, L., Mifsud, V. A., Benedetti, B., & Shatila, A. O. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106747 · Cited by 3
Neuromyelitis optica spectrum disorder (NMOSD): Recent advances and insights from Taiwan
Yang, W.-Y. O., Lin, C., Yu, K.-W., Guo, Y., & Liao, Y. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.10.019 · Cited by 3
Aljarallah, S., Althobaiti, A., Abulaban, A. A., Aldosari, F. M., Alhasan, S., Ali, E. N., Alnajashi, H. A., Mutlaq, A. A., Althubaiti, I. A., Alyafeai, R., et al. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106847 · Cited by 4
Boldrini, V. D. O., & Contentti, E. C. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578817 · Cited by 3
Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases
Stathopoulos, P., & Dalakas, M. C. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00003-1 · Cited by 5
Tanaka, Y. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2634052 · Cited by 3
“Inebilizumab was successfully tested in direct-to-Phase III studies in neuromyelitis optica spectrum disorder (NMOSD) [21], generalized myasthenia gravis (gMG) [22], and IgG4-RD [10], leading to regulatory approvals in all three indications.”
Chen, X., Xiao, J., Zhou, L., Yu, W., Chen, M., Chu, Y., Shang, K., Deng, G., Song, W., Qin, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135061 · Cited by 3
B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease
Wu, H. C., Gombolay, G. Y., Yang, J. H., Graves, J., Christy, A. L., & Xiang, X. M. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01366-7 · Cited by 3
“Inter-estingly, neutropenia has also been described in with inebi-lizumab [ 35], which targets CD19 rather than CD20.”
Yamamura, R., Kinoshita, M., Yasumizu, Y., Yata, T., Kihara, K., Motooka, D., Shiraishi, N., Sugiyama, Y., Beppu, S., Murata, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1508977 · Cited by 3
Wang, Y., & Xu, Y. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106351 · Cited by 3
Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD
Javed, Z., Du, M., Rensel, M. R., Hua, L. H., Hersh, C. M., Abbatemarco, J., Conway, D. S., Ontaneda, D., Cohen, J. A., & Kunchok, A. C. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70160 · Cited by 3
“Compared to the randomized controlled trials of the nMAbs, our cohort included older patients (median age 55), particularly in the satralizumab group (median age 62) [1–4].”
Anti-B-cell therapy in patients with neuromyelitis optica spectrum disorders
Kotov, S. V., Novikova, E. S., & Котов, А. С. (2021) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2021-4-18-24 · Cited by 3
Response to treatment in NMOSD: the Australasian experience
Clarke, L., Bukhari, W., O’Gorman, C., Khalilidehkordi, E., Arnett, S., Woodhall, M. R., Prain, K. M., Parratt, J. D. E., Barnett, M. H., Marriott, M. P., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103408 · Cited by 3
Current view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbations
Сергеевич, К. В., Прахова, Л. Н., & Totolyan, N. A. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-5-69-76 · Cited by 3
Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues
Giovannini, D., Belbézier, A., Baillet, A. C., Bouillet, L., Kawano, M., Dumestre‐Pérard, C., Clavarino, G., Noble, J., Pers, J., Stürm, N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111366 · Cited by 3
Neuromyelitis optic spectrum disorders (NMOSD): from pathogenesis to targeted therapy
Zaitseva, P. A., & Boyko, A. N. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-1s-49-57 · Cited by 5
Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes
Budhram, A., & Sechi, E. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823912-4.00006-2 · Cited by 3
OKUBO, S., Kakumoto, T., Tsujita, M., Muramatsu, K., Fujiwara, S., Hamada, M., Satake, W., & Toda, T. (2024) · Cureus · doi:10.7759/cureus.59938 · Cited by 3
“It is of note that disease-modifying therapies against NMOSD targeting complement factor C5, B-lymphocytes, and interleukin-6 have emerged recently, showing a reduction in relapse risks [8-11].”
BackgroundKamijo, Y., Usuda, M., Matsuno, A., Katoh, N., Morita, Y., Tamaru, F., Kasamatsu, H., & Sekijima, Y. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3593-24 · Cited by 3
Autoantibody-mediated central nervous system channelopathies
Binks, S. N. M., & Irani, S. R. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90820-7.00005-7 · Cited by 3
Perfil clínico y epidemiológico de los pacientes con diagnóstico de neuromielitis óptica.
Caiza Zambrano, F. J., Correa Díaz, E. P., Gualotuña Pachacama, W. A., & Miño Zambrano, J. E. (2021) · Revista Médica-Científica CAMbios HECAM · doi:10.36015/cambios.v20.n1.2021.611 · Cited by 3
Therapie antikörpervermittelter Enzephalomyelitiden
Ayzenberg, I., & Kleiter, I. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01090-4 · Cited by 3
Bridges, J. M., & Chatham, W. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00086-1 · Cited by 3
Inflammatory Demyelinating Diseases of the Central Nervous System
Li, M., & Liu, Q. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_8 · Cited by 3
Myasthenia Gravis — Redemption for B-Cell Depletion
Wolfe, G. I., & Shelly, S. (2025) · New England Journal of Medicine · doi:10.1056/nejme2505722 · Cited by 3
Luxenberg, E. J., Solorio, M., Munger, K., Ayars, A. G., & Wang, Y. (2024) · Neuroimmunology Reports · doi:10.1016/j.nerep.2024.100208 · Cited by 2
Loh, K. M., Cheok, Y. Y., Tang, T. F., Looi, C. Y., Wong, W. F., & Abdullah, S. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf068 · Cited by 2
Li, X., Xue, B., Li, J., Xie, D., Pan, J., Zhu, L.-B., Tong, Q., Lin, J., Zhang, X., Xia, J., et al. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70128 · Cited by 2
“%) related research indicated that some patients remain nonresponsive to these therapies [11, 29, 30].”
Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder
Sakurai, K., Ashikawa, Y., Imaoka, Y., Ohshima, K., Sano, F., Arai, A., Yagishita, N., Araya, N., Nakashima, M., Horibe, E., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5938-25 · Cited by 2
Ikeguchi, R., Shimizu, Y., Kuroda, R., & Todo, K. (2025) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2025.106706 · Cited by 2
Fadda, G., & Palace, J. A. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251367343 · Cited by 3
Baier, E., & Vaglio, A. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2575448 · Cited by 2
“Being originally approved in 2020 for anti-aquaporin 4 (AQP4-) immunoglobulin seropositive neuromyelitis optica spectrum disorder (NMOSD), inebilizumab is an afucosylated, humanized IgG1 κ anti-CD19 monoclonal antibody which functions via ADCC and ADCP [155,156].”
Kim, H. J., Shin, W., Seo, D., Jang, I., Ryu, J., Choi, L., Kim, J. H., Kim, H., Lim, Y., & Lee, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1673508 · Cited by 2
Self-citationApóstolos‐Pereira, S. L., Damasceno, A., Piccolo, A. C., Mendes, M. F., Ferreira, M. L. B., Alvarenga, R. M. P., da Costa, B. K., Sato, D. K., Brum, D. G., de Melo, E. M. V., et al. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1812471 · Cited by 2
Inebilizuma treatment for acute serum AQP4 – IgG neuromyelitis optica: Case report
Zhu, S.-H., Liu, D., Liu, Q., Chen, Q., Shen, Y., Yang, S.-Y., Pan, B.-X., Yang, F., & Jiang, P.-F. (2025) · Medicine · doi:10.1097/md.0000000000045293 · Cited by 2
“[7,8] Long-term follow-up of 75 AQP4-IgG ⁺ patients revealed only 13 relapse events (total 18 attacks) over 4 years of Inebilizumab treatment, with no disability progression and enhanced efficacy by Year 2.”
CAR-T cells in the treatment of neurological autoimmune diseases
Vonberg, F. W., Schroeder, B. E., Edwards, A. E., Sun, B., Keh, R. Y. S., Ashraghi, M. R., Joe, D. K., Gorgoraptis, N., Rees, J. H., Davies, N. W. S., et al. (2026) · Practical Neurology · doi:10.1136/pn-2025-004890 · Cited by 2
Intravenous immunoglobulin use in neurology
Keller, C. W., Dalakas, M. C., & Lünemann, J. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00006-7 · Cited by 2
Metadata
- Authors
- Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., Green, A. J., Aktas, O., Hartung, H.-P., Lublin, F. D., Drappa, J., Barron, G., Madani, S., Ratchford, J. N., She, D., Cimbora, D., & Katz, E.
- Affiliations
- University of California, San Francisco (US)
- University of Colorado Anschutz (US)
- National Cancer Center (KR)
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Fukushima Medical University (JP)
- Max Delbrück Center (DE)
- University of Alabama at Birmingham (US)
- Hospices Civils de Lyon (FR)
- Heinrich Heine University Düsseldorf (DE)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Cree, Bruce A C
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 394
- Issue
- 10206
- Pages
- 1352-1363
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2972221943
- Cited by
- 756
- References
- 26
- Citations by year
- 2026: 105 · 2025: 118 · 2024: 102 · 2023: 101 · 2022: 102 · 2021: 117 · 2020: 101 · 2019: 7
- FWCI
- 58.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Hospices Civils de Lyon
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neuromyelitis optica spectrum disorder, inebilizumab, anti-CD19, B-cell depletion, relapse prevention, disability progression, Expanded Disability Status Scale, treatment-emergent adverse events, autoimmune CNS disease, treatment efficacy and safety, relapse-free survival
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Neuromyelitis Optica, Prospective Studies, Severity of Illness Index, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
